Stem Cell Therapy Market Size, Market Share, Leading Players and Forecast to 2022 – 3rd Watch News

Stem Cell Therapy Market is worth USD 11.99 billion in 2016 and is expected to reach USD 60.94 billion by 2022, growing at a CAGR of 31.1% from 2016 to 2022.

The global stem cell therapy market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the stem cell therapy market.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10325644

KEY BENEFITS OF THE REPORT: Deeper understanding of the strategies adopted by the key players in this market to stay competitive Granular analysis about the growth map of the market during the next five years Comprehensive analysis of the key market players and their market share

KEY PREMIUM INDUSTRY INSIGHTS: The increasing government initiatives and funding from various organizations, the increased spending on research and development, rapid technological advancement in genomics, and the rising awareness about the stem cell therapy are some of the factors fuelling the growth of the stem cell therapy market.

Other factors, such as the robust product pipelines and increasing approval of the new clinical trials are fuelling the growth of the stem cell therapy market further. However, improper infrastructure, insufficient storage systems, and ethical problems are the major restraints for the stem cell therapy market.

MARKET SEGMENTATION: This report analyzes the stem cell therapy market by the following segments:

Stem Cell Therapy Market, by Treatments Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy Stem Cell Therapy Market, by Applications Oncology Central Nervous System Diseases Eye Diseases Musculoskeletal Diseases Wound & Injuries Metabolic Disorders Cardiovascular Disorders Immune System Disorders Stem Cell Therapy Market, by End-users Hospitals Ambulatory Surgical Centers

Request For Full Report:https://www.kennethresearch.com/sample-request-10325644

KEY MARKET PLAYERS: Key players in the stem cell therapy market include:

Vericel Corporation. Stem Cells, Inc. Mesoblast, Ltd. Gamida Cell Osiris Therapeutics, Inc. Chiesi Farmaceutici S.p.A ReNeuron Group, plc

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

View original post here:
Stem Cell Therapy Market Size, Market Share, Leading Players and Forecast to 2022 - 3rd Watch News

Canine Stem Cell Therapy Market 2019 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2023 – 3rd…

The global Canine Stem Cell Therapy market is forecasted to reach a market value of ~US$ XX Mn/Bn by the end of 2029 registering a CAGR growth of around XX% during the forecast period (2019-2029). The recent market report provides a detailed analysis of the current structure of the Canine Stem Cell Therapy market along with the estimated trajectory of the market over the course of the stipulated timeframe.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Canine Stem Cell Therapy market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

The Canine Stem Cell Therapy market report portrays the market share and the application of each of the sub-segments across various verticals.

The Canine Stem Cell Therapy market report explains how the Canine Stem Cell Therapy is being deployed in different sector.

Competitive landscape:

The report ponders over the market scenario in various geographies and highlights the major opportunities, trends, and challenges faced by market players in each region. An in-depth country wise analysis of each major region provides readers a deep understanding of the regional aspects of the market including, the market share, pricing analysis, revenue growth, and more.

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

The market report on the Canine Stem Cell Therapy market addresses some important questions such as:

Crucial data enclosed in the report:

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

View post:
Canine Stem Cell Therapy Market 2019 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2023 - 3rd...

UPMC Children’s Hospital researchers successfully use umbilical cord blood to treat rare genetic disorders — with the potential for many more -…

Dr. Paul Szabolcs. Photo courtesy of UPMC.

A total of 44 children born with rare genetic disorders were successfully treated with umbilical cord blood (UCB), a readily available source of stem cells, in a new study led by UPMC Childrens Hospital of Pittsburgh.

The 44 kids came from 20 states and all have returned home, says the studys senior author Paul Szabolcs, division director of bone marrow transplantation and cellular therapies at UPMC Childrens Hospital. There were 20 diseases amongst the 44.

The plan was to create a universal treatment, rather than finding individual therapies for a host of diseases, which included sickle cell, thalassemia, Hunter syndrome, Krabbe disease, metachromatic leukodystrophy (MLD) and a number of immune deficiencies. Its the biggest trial of its kind to date.

The results of the study were just published in the journal Blood Advances.

Its a treatment that has a lot of potential upsides, including cost.

There has been a lot of emphasis placed on cool new technologies that might address these diseases, but even if they prove effective those arent available to most centers, says Szabolcs. The regimen we developed is more robust, readily applicable and will remain significantly less expensive.

The children who participated received intravenous cord blood, donated from the umbilical cords and placentas of healthy babies, which was frozen until needed.

Although UCB transplants have been done for 25 years, survival has not been stellar, and procedure-related mortality has been high, says Szabolcs. Some centers have considered 20% mortality acceptable, while we think the ultimate goal is getting near zero percent mortality due to procedure-related complications.

The treatment was designed to deal with patients immune system reactions.

We approached the topic with the mindset to design a regimen that carefully balances low-intensity chemo (bringing safety) with sufficiently effective immunotherapy to blast away the patients immune system, therefore preventing rejection, says Szabolcs. Rejection has been a common failure when other centers explored the reduced-intensity conditioning (RIC) approach with cord blood. We are the first to prove the RIC is able to give reliable results in long-term engraftment.

The regimen isnt toxic to the heart, lungs, liver and kidney. Post-infusion complications have been mild. None of the children experienced chronic graft-versus-host disease.

A novel plug-in immune boost is offered by us for the first time ever, using a tiny fraction of the cord blood (donor lymphocyte infusion) that we refreeze on transplant day and infuse one to two months after to jumpstart immune recovery from this tiny fraction, explains Szabolcs.

The donor and recipient dont have to have matching immune profiles.Thats huge for ethnic minorities, says Szabolcs.

Cord blood grafts permit some mismatch, although outcomes tend to get incrementally worse with each mismatch. We have found a suitable cord blood unit for all 50 patients we have searched, even for complex ethnic cases such as Caribbean-African heritage. With our combination of sequential chemo and immune therapy, we were able to overcome the risks of mismatches and minimize the impact of rejection.

Thirty children in the trial had metabolic disorders, reflecting improper enzyme function. All but one exhibited symptoms of neurodevelopmental delays before the trial started. Within a year of receiving cord blood, all stopped neurological decline and some began to acquire new skills.

There has been a stagnation of outcomes in this field, just changing one chemotherapy agent for another, not a true evolution, says Szabolcs. We designed an approach now proven to be efficacious for at least 20 diseases. And we believe it might be effective for many, many more.

Since the paper was submitted, the researchers have used this approach to treat other diseases, including some in adults.

Theres been a lot of interest in adopting this regimen around the world.

There have been already some aspects that have been copied as we reported preliminary data at scientific meetings,but with the full recipe published now more centers will be able to adopt, says Szabolcs. There has already been interest in Europe, and I predict it will be tried in the Americas and Asia as well.

Funding for the study was provided by the National Heart, Lung and Blood Institute.

medical researchrare genetic disordersupmc children's hospitalUPMC Children's Hospital of Pittsburgh

Here is the original post:
UPMC Children's Hospital researchers successfully use umbilical cord blood to treat rare genetic disorders -- with the potential for many more -...

Autologous Stem Cell and Non-Stem Cell Based Therapy Market Growth and Future Analysis – 3rd Watch News

The global autologous stem cell and non-stem cell based therapy market is growing significantly due to high incidences of cancer and cardiovascular diseases, and presence of large number of patients requiring transplantation. The lack of service providers in the autologous stem cell market, and the massive unexplored autologous stem cell and non-stem cell based therapy market in the emerging economies, are creating ample growth opportunities for the global autologous stem cell and non-stem cell based therapy market.

Request for sample copy of this report: https://www.psmarketresearch.com/market-analysis/autologous-stem-cell-and-non-stem-cell-based-therapy-market/report-sample

The advanced research and development activities and new product developments by the major players are supporting the demand for cost effective and efficient autologous stem cell and non-stem cell based therapy platforms.

The usage of multipotent stromal cell (mesenchymal stem cell) transplantation in multiple sclerosis is a trend, in the global autologous stem cell and non-stem cell based therapy market. In autologous stem cell and non-stem cell based therapy, an individuals stem or non-stem cells are cultured outside the body and then transferred back into the body. The autologous cellular therapies do not require separate donor, instead it utilizes stem or non-stem cells from the individual who needs treatment for a particular disease.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=autologous-stem-cell-and-non-stem-cell-based-therapy-market

Asia-Pacific is the fastest growing region in the global autologous stem cell and non-stem cell based therapy market. The major reasons for the fastest growth in the region are increasing healthcare expenditure, increasing autologous stem cell and non-stem cell based therapy related research activities, improving healthcare infrastructure. Moreover, the autologous stem cell and non-stem cell based therapy market is growing rapidly, due its capability of treating a range of diseases such as autoimmune, cancer, and cardiovascular, in the emerging economies such as India and China.

This study covers

Here is the original post:
Autologous Stem Cell and Non-Stem Cell Based Therapy Market Growth and Future Analysis - 3rd Watch News

Impact of COVID-19 on Avascular Necrosis Market Emerging Growth And Forecast to 2027 | Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon…

Coherent Market Insights has recently published the Global research Report Titled Avascular Necrosis Market. The study provides an overview of current statistics and future predictions of the Avascular Necrosis Market. The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

The Global Avascular Necrosis Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the in each region. Various methodological tools are used to analyze the growth of the worldwide Avascular Necrosis Market.

To learn more about this report, request a samplecopy:https://www.coherentmarketinsights.com/insight/request-sample/2218

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Prominent Key Players Covered in the report:

Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA, Integra LifeSciences Corporation, K-Stemcell Co Ltd., Medtronic Plc, Merck KGaA, Pfizer Inc., Sanofi SA, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings. Manufacturers are focusing on advancements in treatment technologies such as gene therapy and stem cell-based treatment for avascular necrosis.

Detailed Segmentation:

By Type:Trauma Related Avascular NecrosisNon-Trauma Related Avascular NecrosisGlobal Avascular Necrosis Market, By Treatment:Drug BasedSurgeryCore decompression surgeryOsteotomyBone graftTotal joint replacement

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

How Does This Market Insights Help?

Avascular Necrosis Market share (regional, product, application, end-user) both in terms of volume and revenue along with CAGR

Key parameters which are driving this market and restraining its growth

What all challenges manufacturers will face as well as new opportunities and threats faced by them

Learn about the market strategies that are being adopted by your competitors and leading organizations

To gain insightful analyses of the market and have a comprehensive understanding of the Avascular Necrosis Market and its commercial landscape

Key Pointers Covered in the Industry Trends and Forecast to 2027

Current and future of global Avascular Necrosis Market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

Regions/Countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/2218

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

In conclusion, the Avascular Necrosis Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Customization of the Report:

Coherent Market Insights also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Need a discount?

Request discount for this report @https://www.coherentmarketinsights.com/insight/request-discount/2218

Note: *The discount is offered on the Standard Price of the report.an

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact:

US +1-206-701-6702

UK +44-020 8133 4027 [emailprotected]

Read more from the original source:
Impact of COVID-19 on Avascular Necrosis Market Emerging Growth And Forecast to 2027 | Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon...

Vor Biopharma Appoints Daniella Beckman to its Board of Directors – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Daniella Beckman to its Board of Directors. The appointment of Ms. Beckman, an experienced biotech finance leader who currently serves as Chief Financial Officer at Tango Therapeutics, follows the hiring of Christopher Slapak, MD, as Chief Medical Officer and the completion of a $110 million Series B financing round.

Daniella is a fantastic addition to our Board of Directors and we are honored to have her join at this important time for our company, said Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer. Her expertise in financial strategy and operations will be of great value to us as we leverage our recent Series B funding round to further advance our lead product candidate VOR33 towards clinical trials and continue to build out our portfolio.

Ms. Beckman joins Vor with deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Ms. Beckman oversees finance, investor relations, and business development. Prior to joining Tango, Ms. Beckman was a consultant to early-stage biotechnology companies, leading financial activities and building companies financial infrastructures. She also served as Interim Chief Financial Officer for Neon Therapeutics. Previously, Ms. Beckman was Chief Financial Officer of Idenix Pharmaceuticals, where she was responsible for finance, investor relations, and IT until the company was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers (PwC). Ms. Beckman received her BA in business administration and accounting from Boston University and is a Certified Public Accountant in Massachusetts. In addition to Vor, Ms. Beckman also serves on the Board of Directors of Translate Bio as Chair of the Audit and the Nomination and Governance Committees.

The Series B financing is testament to the potential for eHSCs to improve the treatment paradigm for patients with blood cancers such as acute myeloid leukemia, Ms. Beckman said. I am looking forward to working with and supporting Vor as the company continues to innovate to address cancer patients in need.

About Vor Biopharma

Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.

About VOR33

Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, we believe that CD33 will become a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from acute myeloid leukemia.

Read this article:
Vor Biopharma Appoints Daniella Beckman to its Board of Directors - Business Wire